New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2016 Apr;22(4):768-770
Date
01/09/2016Pubmed ID
26743343Pubmed Central ID
PMC4801777DOI
10.1016/j.bbmt.2015.12.021Scopus ID
2-s2.0-84960472606 (requires institutional sign-in at Scopus site) 5 CitationsAbstract
Hematologic response criteria in light chain (AL) amyloidosis were updated in 2012 to incorporate free light chain responses. These criteria have been validated in autologous hematopoietic cell transplantation in AL at 6 and 12 months after transplantation. Using a transplantation registry, we assessed day 100 responses in AL amyloidosis. We validate the prognostic significance of the new criteria at this time point. Further, we show that patients who do not achieve at least a very good partial response by this time point have equally worse outcomes, regardless of depth of response (partial versus no response). Thus, we conclude that the new criteria help identify the poor responders by day 100 after transplantation and that this subset of patients should be studied for early evaluation in consolidation trials.
Author List
D'Souza A, Huang J, Hari PAuthors
Anita D'Souza MD Associate Professor in the Medicine department at Medical College of WisconsinParameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdultAged
Amyloidosis
Biomarkers
Female
Hematopoietic Stem Cell Transplantation
Humans
Immunoglobulin Light Chains
Immunoglobulin Light-chain Amyloidosis
Male
Melphalan
Middle Aged
Myeloablative Agonists
Prognosis
Registries
Risk Assessment
Survival Analysis
Transplantation, Autologous
Treatment Outcome
